Cochrane Lab Reports on Harm Reduction in Heated Tobacco Products

Jul.30.2022
Cochrane Lab Reports on Harm Reduction in Heated Tobacco Products
New Cochrane lab research suggests that switching from traditional cigarettes to HTPs may lower the risk of certain illnesses.

The latest study on heated tobacco products has been released by the Cochrane laboratory. The report follows standard Cochrane screening and data extraction methods, and the majority of the data from the study suggests that harmful substance exposure associated with cancer, heart disease, and respiratory issues is lower with HTP compared to traditional cigarettes. This means that transitioning to HTP may decrease the risk of developing these diseases. However, the research team notes that due to the short duration of the studies, the data is not conclusive enough to fully determine these results.


Researchers emphasized that while they did not find any studies indicating whether HTP helps smokers quit, two Japanese research reports indicated that cigarette sales declined after the introduction of IQOS into the market.


In fact, during a recent online seminar with Kumamaru Hiroya, the Deputy Director of Kawasaki AOI General Hospital, it was stated that while nicotine replacement therapy (NRT), such as nicotine patches, has not produced the expected results, HTP has. Hiroya confirmed that since the local launch of heated tobacco products, the smoking rate has started to significantly decrease.


In short, after attempting nicotine replacement therapy guidance, it did not achieve significant success. However, since 2014, Japan has officially launched three types of heated tobacco products, which have penetrated 25% of the overall smoking population. So far, these products have successfully reduced Japan's smoking rate by 30% within three to four years," said Hiroya in a recent online seminar.


HTP's Aerosol Particles


In other studies, researchers from Kaunas University of Technology in Lithuania conducted an analysis in 2019 examining the levels of aerosol particles, carbonyls, and nicotine in the indoor air of HTPs (referred to as THS in the study). They compared the indoor concentrations of substances such as formaldehyde, acetaldehyde, benzene, toluene, nicotine, and particulate matter 2.5 in THS to the concentrations of traditional cigarettes and other known air pollutants.


According to data, compared to cigarette smoke and other pollutants, any adverse effects of thirdhand smoke (THS) on indoor air quality are negligible. "The use of THS results in several analytes, including nicotine, acetaldehyde, PM2.5 and PNC, being statistically significantly increased, but the levels obtained are much lower compared to those produced by conventional cigarettes (CC) under the same conditions (approximately 16 times, 8 times and 28 times lower for nicotine, acetaldehyde, PNC and PM2.5, respectively).


According to authors Violeta Kauneliene, Marija Meisutovic-Akhtarieva, and Dainius Martuzevicius, "In a controlled environment, the concentration of formaldehyde, toluene, and PM2.5 in THS (and vape) is much lower than in most other sources of pollution, such as traditional cigarettes and hookah.


Click to view the original research report.


Sorry, I cannot complete this task as there is no original text to translate. Please provide the original text to be translated.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
FDA’s Center for Tobacco Products detailed new PMTA review data and process changes at the 2026 FDLI conference. Pending PMTAs fell from about 450,000 at the start of 2025 to 135,000 by September 2026. CTP also discussed its 180-day review goal, current sPMTA pilot, alternate-supplier planning, more than 50,300 pending SE reports, and lessons from the nicotine pouch pilot already being applied to ENDS review.
Regulations
Oct.07
2Firsts Data|China’s Vape-Related Exports Rose 3.3% in August 2026 as UK Shipments Jumped 51.4% and U.S. Exports Fell 12.4%
2Firsts Data|China’s Vape-Related Exports Rose 3.3% in August 2026 as UK Shipments Jumped 51.4% and U.S. Exports Fell 12.4%
China exported $979 million of vape-related products in August 2026, up 3.3% from a year earlier but down 6.4% from July. The UK replaced the U.S. as the main source of growth: UK-bound shipments jumped 51.4% to a 2026 high of $177 million, while exports to the U.S. fell 12.4% to $339 million. Shipments to markets outside the U.S. increased 14.2%, broadening growth beyond the market that had driven July’s rebound.
News
Sep.23 by 2Firsts Perspectives
Kelly White Bets on Female Consumers as Nicotine Pouch Competition Intensifies | 2Firsts Interview
Kelly White Bets on Female Consumers as Nicotine Pouch Competition Intensifies | 2Firsts Interview
Swedish nicotine pouch brand Kelly White is building its strategy around adult female consumers. Founder and CEO Sophia Wilsby told 2Firsts that women accounted for around 70% of the brand’s repeat customers on HAYPP in Sweden in 2025. The interview explores female consumer segmentation, product and design differentiation, gender stereotypes, packaging regulation, and how independent brands can compete with global players such as ZYN and VELO while considering funding, partnerships and future ownership options.
Business
Sep.24
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Philip Morris International (PMI) has launched ZYN Melts in the UK, introducing a fully dissolvable oral nicotine tablet format alongside the brand's existing nicotine pouches. The range includes Cool Mint and Peppermint, each offered at 1mg and 2mg of nicotine per tablet, creating four SKUs. Each can contains 20 tablets and is priced at £6.50 in the UK. Unlike ZYN nicotine pouches, Melts are placed between the upper lip and gum and dissolve completely during use.
News
Sep.29 by 2Firsts Perspectives
Australia Extends Illicit Tobacco Crackdown From Tougher Penalties to Customs and Logistics Supply Chains
Australia Extends Illicit Tobacco Crackdown From Tougher Penalties to Customs and Logistics Supply Chains
Australia's federal government introduced a new illicit tobacco enforcement bill on September 10 that would strengthen evidentiary presumptions, representative sampling, seizure and forfeiture procedures, proceeds-of-crime powers and obligations for customs and logistics operators. The proposal follows the Combatting Illicit Tobacco Act 2026, which took effect in August and increased penalties while expanding investigative and asset-recovery tools. Together, the reforms extend Australia's crackdown from tougher criminal sanctions into import, logistics and evidentiary enforcement.
Sep.14
Product | BAT Expands VELO Travellers’ Collection With Mexico, Spain and Sweden Summer Edition Nicotine Pouches
Product | BAT Expands VELO Travellers’ Collection With Mexico, Spain and Sweden Summer Edition Nicotine Pouches
British American Tobacco (BAT) Global Travel Retail has expanded the VELO Travellers’ Collection with three new Summer Editions: Mexico, Spain and Sweden. Inspired by destination themes, the new nicotine pouch variants are designed for global travel-retail channels. The launch further strengthens VELO’s positioning as a travel-retail exclusive product collection.
Aug.27